CSIMarket
 
Gain Therapeutics inc  (GANX)
Other Ticker:  
 
 
Price: $4.2900 $0.01 0.234%
Day's High: $4.4318 Week Perf: -8.14 %
Day's Low: $ 4.22 30 Day Perf: -9.3 %
Volume (M): 184 52 Wk High: $ 6.19
Volume (M$): $ 787 52 Wk Avg: $3.93
Open: $4.34 52 Wk Low: $2.00



 Market Capitalization (Millions $) 54
 Shares Outstanding (Millions) 13
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Gain Therapeutics Inc
Gain Therapeutics Inc. is a biotechnology company that focuses on developing small molecule therapeutics to treat rare genetic diseases and neurodegenerative disorders. The company specializes in developing drugs that target misfolded proteins, which are a common cause of these diseases. Gain Therapeutics utilizes proprietary technology platforms and computational algorithms to identify potential drug candidates and design molecules that can stabilize or restore the function of the misfolded proteins. By addressing the root cause of the diseases, the company aims to provide breakthrough treatments that can significantly improve the lives of patients. Gain Therapeutics is headquartered in Spain and Switzerland, and collaborates with leading academic institutions and research organizations to advance its drug development programs.


   Company Address: 4800 Montgomery Lane Bethesda 20814 MD
   Company Phone Number: 500-1556   Stock Exchange / Ticker: NASDAQ GANX
   GANX is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Gain Therapeutics' GT-02287: Revamping Parkinson's Disease Treatment with Unprecedented Efficacy

Published Tue, Mar 5 2024 1:00 PM UTC

Gain Therapeutics Makes Groundbreaking Progress in the Treatment of Parkinson's DiseaseGain Therapeutics, a leading biotechnology company, presented groundbreaking data at the AD/PD 2024 Conference, shedding light on the impressive mechanism of action of their clinical stage GCase regulator, GT-02287, for the treatment of Parkinson's disease. The findings provide robust evid...

Clinical Study

Promising Results from Gain Therapeutics' Clinical Trial on GT-02287: A Novel Small Molecule Therapy for GBA1 Parkinson's Disease

Published Tue, Feb 27 2024 7:00 PM UTC

Gain Therapeutics, a clinical-stage biotechnology company, has recently initiated the Multiple Ascending Dose (MAD) part of the Phase 1 clinical trial for GT-02287, their lead drug candidate targeting GBA1 Parkinson's disease. In this article, we will delve into the significance of this trial and the potential implications for patients suffering from this debilitating neurod...

Clinical Study

A Remarkable Leap in Parkinson?s Treatment: Gain Therapeutics GT-02287 Demonstrates Complete Restoration of Motor Function in Mouse Models.

Published Tue, Feb 6 2024 1:00 PM UTC

Pharmaceutical innovation has once again shown its potential to redefine medical possibilities. Ground-breaking research from Gain Therapeutics has revealed that their therapeutic agent, GT-02287, has demonstrated the potential to completely restore motor function in Parkinson's disease mouse models. These compelling results were recently unveiled at the 20th WORLDSymposium....

Management Announcement

Gain Therapeutics CEO Matthias Alder Highlights Growth Potential and Future Plans for Shareholders

Published Wed, Jan 31 2024 1:01 PM UTC



Gain Therapeutics, a renowned biotechnology company pioneering the breakthrough discovery and development of allosteric small molecule therapies, has recently provided an operational update through a letter addressed to shareholders from its President and Chief Executive Officer, Matthias Alder. The letter sheds light on the company's progress, achievements, and fu...

Clinical Study

GT-02287: A Promising Breakthrough in Parkinson's Disease Therapeutics

Published Tue, Jan 2 2024 1:01 PM UTC

Advancements in Therapeutic Approach for Parkinson's Disease: The Potential of GT-02287Abstract:Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the brain, leading to motor dysfunction, cognitive impairment, and other debilitating symptoms. While current treatments primarily focus on managing symptoms, there is an ...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com